This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Pain severity-BPI
Timeframe: From Baseline up to 3 Months
Pain severity-VAS
Timeframe: From Baseline up to 3 Months
Pain severity-NRS
Timeframe: From Baseline up to 3 Months
Quality of Life (EORTC PAN26)
Timeframe: From Baseline up to 3 Months
Quality of Life (EORTC C30)
Timeframe: From Baseline up to 3 Months
Quality of Life (NFHSI)
Timeframe: From Baseline up to 3 Months
Concomitant Analgesic/Narcotic Use
Timeframe: From Baseline up to 3 Months